ReviewAnnals of thoracic medicine
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
Review in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 68 citations in OpenAlex.
- Allergic bronchopulmonary aspergillosis in cystic fibrosis: Case-control study from the French registry.Medical mycology · 2025Article
- Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to Aspergillus fumigatus in a mouse model of cystic fibrosis.PLoS pathogens · 2025Article
- Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.Journal of fungi (Basel, Switzerland) · 2024Review
- Aspergillus and the Lung.Seminars in respiratory and critical care medicine · 2024Review
- Exploring the immunopathology of type 2 inflammatory airway diseases.Frontiers in immunology · 2024Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Infection, Allergy, and Inflammation: The Role ofMicroorganisms · 2023Review
- The value of bronchocele attenuation in pulmonary computed tomography in assessment of allergic bronchopulmonary aspergillosis in the background of cystic fibrosis: A cross-sectional study.Annals of medicine and surgery (2012) · 2022Article
- Clinical characteristics of people with cystic fibrosis and frequent fungal infection.Pediatric pulmonology · 2022Article
- Review
- Mucosal Immunity in Cystic Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Pediatric usage of Omalizumab: A promising one.The World Allergy Organization journal · 2021Review
- Emerging Fungal Threats in Cystic Fibrosis.Mycopathologia · 2021Review
- Fungal Infection and Inflammation in Cystic Fibrosis.Pathogens (Basel, Switzerland) · 2021Review
- Bacterial Interactions withMicroorganisms · 2021Review
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Biology and function of exo-polysaccharides from human fungal pathogens.Current clinical microbiology reports · 2020Article
- Urban Life as Risk Factor for Aspergillosis.Frontiers in cellular and infection microbiology · 2020Article
- Frequent Pet Contact as Risk Factor for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis.Frontiers in cellular and infection microbiology · 2020Article
- Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.